A recent market research report from Technavio predicts that the U.S. immunoassay clinical analyzer market will grow at a healthy CAGR of around 6% during 2016 – 2020.
Today, immunoassay analyzers are available as floor and benchtop models. Modern devices offer comprehensive testing for infectious diseases, thyroid, fertility and anemia, as well as assays for cancer markers, cardiac analysis, allergy testing and therapeutic drug monitoring. Modern devices come with a wide range of advanced features such as a comprehensive disease-focused menu, streamlined sample handling, continuous sample loading, simplified operation, and excellent precision and sensitivity.
According to the Technavio report, the factors that influencing the growth of this market during the forecast period are:
- The growing demand for high-throughput screening with the aid of immunoassays
- Next-generation immunodiagnostics that provide high quality test results
- Modern analyzers’ ability to improve the workflow and turnaround time for tests
- The rising popularity of immunoassay analyzers due to their compact size and cost-efficiency
The report classifies the market based on application and product type. Based on application, the market is divided in to Oncology and Endocrinology, Hepatitis and Retrovirus testing, Infectious disease testing and GI stool testing. The oncology and endocrinology segment is expected to be the fastest-growing market segment during the forecast period, with an impressive market growth rate of nearly 7% by 2020.
Product types include instruments, services and spare parts. It is expected that the instruments segment will account for more than 75% of the total market share by 2020. This segment’s growth can be attributed to the high popularity of instruments such as immunoassay analyzers in hospitals and clinical laboratories for automated biochemical testing. The key vendors in the market include Abbott Diagnostics, Beckman Coulter, Roche Diagnostics and Siemens Healthcare Diagnostics.